158 related articles for article (PubMed ID: 25417773)
1. Inhibitory effect of ketoconazole and voriconazole on the pharmacokinetics of carvedilol in rats.
Wang L; Wang S; Chen M; Chen X; Lin Y; Hu X; Huang X; Li X; Hu G
Drug Dev Ind Pharm; 2015; 41(10):1661-6. PubMed ID: 25417773
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous quantification of carvedilol and its metabolites in rat plasma by ultra performance liquid chromatography tandem mass spectrometry and pharmacokinetic application.
Li J; Wang L; Wang S; Chen M; Gu E; Hu G; Ge R
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Jan; 974():138-46. PubMed ID: 25463209
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Apatinib on the Metabolism of Carvedilol Both in vitro and in vivo.
Lin D; Wang Z; Li J; Wang L; Wang S; Hu GX; Liu X
Pharmacology; 2016; 97(1-2):31-7. PubMed ID: 26569478
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat.
Lin G; Wang C; Qiu X; Wang Z; Han A; Xu T; Kan X; Hu G
Drug Dev Ind Pharm; 2014 Dec; 40(12):1616-22. PubMed ID: 24053419
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro.
Shen L; Wang J; Yi Y; Ye C; Wang R; Xia G; Yu C; Tu F; Xu J; Zheng Z
Drug Test Anal; 2019 Apr; 11(4):595-600. PubMed ID: 30370647
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous quantification of vortioxetine, carvedilol and its active metabolite 4-hydroxyphenyl carvedilol in rat plasma by UPLC-MS/MS: Application to their pharmacokinetic interaction study.
Huang Y; Zheng S; Pan Y; Li T; Xu ZS; Shao MM
J Pharm Biomed Anal; 2016 Sep; 128():184-190. PubMed ID: 27262994
[TBL] [Abstract][Full Text] [Related]
7. Effects of ketoconazole, voriconazole, and itraconazole on the pharmacokinetics of apatinib in rats.
Lou D; Cui X; Bao SS; Sun W; Pan WH; Chen MC; Dong YY; Hu GX; Chen RJ; Wang Z
Drug Dev Ind Pharm; 2019 Apr; 45(4):689-693. PubMed ID: 30632818
[TBL] [Abstract][Full Text] [Related]
8. Chiral analysis of carvedilol and its metabolites hydroxyphenyl carvedilol and O-desmethyl carvedilol in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical pharmacokinetic study.
Nardotto GHB; Coelho EB; Marques MP; Lanchote VL
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Mar; 1015-1016():173-180. PubMed ID: 26927877
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory Effect of Citalopram on the Pharmacokinetics of Carvedilol in Rats and in vitro Models.
Abrudan MB; Muntean DM; Popa DS; Gheldiu AM; Neag MA; Vlase L
Pharmacology; 2017; 100(5-6):301-307. PubMed ID: 28848215
[TBL] [Abstract][Full Text] [Related]
10. Effects of myricetin on the bioavailability of carvedilol in rats.
Lee W; Woo ER; Choi JS
Pharm Biol; 2012 Apr; 50(4):516-22. PubMed ID: 22132944
[TBL] [Abstract][Full Text] [Related]
11. Effects of cilostazol on the pharmacokinetics of carvedilol after oral and intravenous administration in rats.
Lim TH; Cho YA; Choi DH
J Physiol Pharmacol; 2015 Aug; 66(4):591-7. PubMed ID: 26348083
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the inhibitory effect of ketoconazole, voriconazole, fluconazole, and itraconazole on the pharmacokinetics of bosentan and its corresponding active metabolite hydroxy bosentan in rats.
Chen M; Zhang X; Chen Y; Sun W; Wang Z; Huang C; Hu G; Chen R
Xenobiotica; 2020 Mar; 50(3):280-287. PubMed ID: 31199171
[TBL] [Abstract][Full Text] [Related]
13. Analysis of carvedilol enantiomers in human plasma using chiral stationary phase column and liquid chromatography with tandem mass spectrometry.
Poggi JC; Da Silva FG; Coelho EB; Marques MP; Bertucci C; Lanchote VL
Chirality; 2012 Mar; 24(3):209-14. PubMed ID: 22271587
[TBL] [Abstract][Full Text] [Related]
14. UPLC-MS/MS assay for the simultaneous quantification of carvedilol and its active metabolite 4'-hydroxyphenyl carvedilol in human plasma to support a bioequivalence study in healthy volunteers.
Patel DP; Sharma P; Sanyal M; Singhal P; Shrivastav PS
Biomed Chromatogr; 2013 Aug; 27(8):974-86. PubMed ID: 23483571
[TBL] [Abstract][Full Text] [Related]
15. Stereoselective analysis of carvedilol in human plasma and urine using HPLC after chiral derivatization.
Peccinini RG; Ximenes VF; Cesarino EJ; Lanchote VL
Biopharm Drug Dispos; 2008 Jul; 29(5):280-8. PubMed ID: 18551504
[TBL] [Abstract][Full Text] [Related]
16. Is urethane-chloralose anaesthesia appropriate for pharmacokinetic-pharmacodynamic assessment? Studies with carvedilol.
Bertera FM; Di Verniero CA; Mayer MA; Bramuglia GF; Taira CA; Höcht C
J Pharmacol Toxicol Methods; 2009; 59(1):13-20. PubMed ID: 18973819
[TBL] [Abstract][Full Text] [Related]
17. Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats.
Kim MS; Baek IH
Eur J Pharm Sci; 2018 Jan; 111():13-19. PubMed ID: 28942006
[TBL] [Abstract][Full Text] [Related]
18. A validated enantioselective LC-MS/MS assay for the simultaneous determination of carvedilol and its pharmacologically active 4'-hydroxyphenyl metabolite in human plasma: application to a clinical pharmacokinetic study.
Furlong MT; He B; Mylott W; Zhao S; Mariannino T; Shen J; Stouffer B
J Pharm Biomed Anal; 2012 Nov; 70():574-9. PubMed ID: 22709607
[TBL] [Abstract][Full Text] [Related]
19. Differential Impacts of Azole Antifungal Drugs on the Pharmacokinetic Profiles of Dasatinib in Rats by LC-MS-MS.
Luo X; Xue X; Li T; Zhang Y; Huang L; Cheng G
Curr Drug Metab; 2020; 21(13):1022-1030. PubMed ID: 33092505
[TBL] [Abstract][Full Text] [Related]
20. Comparison of different pharmacodynamic models for pharmacokinetic-pharmacodynamic (PK-PD) modeling of carvedilol.
Liu XY; Wang BJ; Yuan GY; Guo RC
Yao Xue Xue Bao; 2009 Apr; 44(4):406-11. PubMed ID: 19545060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
